middle.news
Orthocell Accelerates US Rollout of Remplir, Eyeing Cash Breakeven Below 1% Market Share
9:12am on Monday 2nd of February, 2026 AEDT
•
Healthcare
Read Story
Orthocell Accelerates US Rollout of Remplir, Eyeing Cash Breakeven Below 1% Market Share
9:12am on Monday 2nd of February, 2026 AEDT
Key Points
Remplir US sales growing steadily with 70% repeat surgeon use
Cash breakeven targeted at under 1% of US peripheral nerve repair market
Manufacturing expansion underway to quadruple capacity and reduce costs
Fully funded with cash reserves expected to remain above $20 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE